Bouygues wins COVID-19 vaccine build

Published: 18-Jan-2021

Bouygues Energies & Services has been selected by Valneva for the turnkey design and build of their manufacturing facility

Bouygues Energies & Services, a subsidiary of Bouygues Construction, has been selected by Valneva, a speciality vaccine company, for the turnkey design and build of their manufacturing facility, located in Livingston, Scotland.

The manufacturing facility is formed of:

  • A new Multi Vaccine Facility (MVF), adjacent to the existing vaccine facility, which will be designed to EU GMP Grade A to D cleanroom standards. The facility will house two manufacturing streams and QC testing laboratories uninterruptedly working to produce Valneva's inactivated whole-virus COVID-19 vaccine. All areas where the live virus will be handled will be designed to meet the requirements of ACDP containment level 3 as agreed with the Health and Safety Executive.
  • A new warehouse facility that will consist of temperature-controlled storage areas along with goods in and off-loading bays.
  • An energy centre that will shelter all essential plant services to serve the main manufacturing facility and associated labs.
  • Shared hub facilities that will comprise the main site entrance, offices, employee's welfare areas as well as the staff car park and the access road for the delivery.

Bouygues, as the main design and build partner, will be responsible for the industrial park development, as a turnkey design and build solution.

The facility will be designed to EU GMP Grade A to D cleanroom standards

This project started with a site master planning and detailed design now progressing to engineering, build, commissioning and validation of the new facilities which will be delivered on a phased basis. The master planning of the industrial park has started in July 2020, and the production of vaccines will commence in the first half of 2021.

Managing Director and CEO of Bouygues, Steven Weir, said: "We have an excellent track record working with Valneva and are extremely proud to continue with them on this landmark project. We hope that in doing so we can play our small part in the production of this very important vaccine."

Bouygues is committed to supporting Valneva to scale up its manufacturing capacity to be able to produce required doses of the COVID-19 vaccine. The facility will also ensure the readiness for future vaccine development and manufacturing.

David Lawrence, Acting CFO of Valneva added: "Our partnership with the UK Government will ensure that our Livingston facility is well prepared to deliver a COVID-19 vaccine during 2021 and beyond. Bouygues Energies & Services is a tried and tested partner, we're working closely with them to ensure that the project is delivered as quickly as possible."

With 50 years of experience in controlled critical environments, Bouygues Energies & Services offers a high-level of expertise delivering state-of-art cleanroom, laboratory and manufacturing facilities.

You may also like